Olmesartan blocks the vasoconstrictor effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in vascular smooth muscle. Chlorthalidone is a benzothiadiazide (thiazide)-related diuretic with a long duration of action. It primarily acts on the distal renal tubule, inhibiting NaCl¯ reabsorption.
One tablet once daily.
Contraindicated in patients with anuria and in patients with known hypersensitivity to any active ingredients or any other component of this product.
Observe for signs and symptoms of hypotension in volume- or salt-depleted patients with treatment initiation. Should be used in caution in patients with severe renal disease and hepatic impairment. Hypokalemia and other electrolyte abnormalities, including hyponatremia and hypochloremic alkalosis, are common in patients receiving chlorthalidone. Serum electrolytes should be determined before initiating therapy and at periodic intervals during therapy.
Not recommended for use in pregnancy. It is not known whether olmesartan is excreted in human milk. Avoid use during lactation. Safety and efficacy in pediatric patients has not been established.
Olmesartan - used concomitantly with NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect.Chlorthalidone- Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. Adjustment the dosage of insulin and oral anti-diabetic agents may be required. Concomitant administration of certain NSAIDs may reduce the diuretic and antihypertensive activity of chlorthalidone.
The most common adverse reactions include: dizziness, hypotension,and electrolyte imbalance.
Doctors
Nurses
PRODUCT DETAILS VIEW ALL PRODUCTS